Gilead Sciences disclosed in May 2026 WARN notices that it will lay off 192 employees at the two facilities of newly acquired Arcellx. The cuts split as 108 jobs at the Redwood City, California site (800 Bridge Parkway) and 84 jobs at the Rockville, Maryland site (800 King Farm Boulevard). The reduction is slated to begin at the end of June 2026.
The cuts arrive just weeks after Gilead's $7.8 billion acquisition of Arcellx formally closed. Arcellx, a CAR-T cell-therapy biotech focused on hematologic malignancies, had a pre-acquisition headcount of approximately 209. The 192 cuts represent roughly 92% of that workforce, effectively wiping out the legacy Arcellx organization as a standalone unit inside Gilead.
Gilead said in a statement that the integration decisions were not taken lightly and that the company is focused on supporting affected employees through the transition. A small subset of Arcellx scientific and clinical leadership is expected to be retained inside Gilead's existing cell therapy organization, which is housed under Kite Pharma, the cell-therapy subsidiary Gilead acquired in 2017 for $11.9 billion.
This is the second time Gilead has dismantled a multi-billion-dollar cell therapy acquisition's standalone workforce within a year of closing. The Kite playbook in 2017 produced a similar pattern of consolidation into Gilead's master research operation. The Arcellx repeat suggests Gilead now treats post-close headcount integration as a standardized component of its M&A model rather than a one-off restructuring decision.
The 92% post-acquisition workforce cut is the steepest M&A integration ratio seen in large-cap pharma in 2026. Bristol Myers Squibb's Celgene integration over 2019-2021 cut roughly 30% of the combined R&D headcount over three years. Gilead's Arcellx action is happening inside the first quarter post-close at a 92% rate.
For the broader CAR-T sector, the signal is unambiguous. Arcellx's pre-acquisition pitch was a differentiated cell therapy platform for multiple myeloma. Gilead's decision to wind down most of that platform's operational footprint suggests the acquirer values the asset, not the team. Cell therapy talent in Redwood City and Rockville now flows back into the labor market just as the broader biotech funding environment remains compressed. Watch the second-quarter 10-Q for Gilead's commentary on the consolidated cell-therapy pipeline structure post-integration.